Clinical Trials

140 enrolled

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

GastrointestinalOther solid neoplasmThoracic

514 enrolled

Metastatic Solid Tumors

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

555 enrolled

Stomach Neoplasms

NCT06312982 2026-01-13

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

Phase 2/3 Recruiting

375 enrolled

Locally Advanced Rectal Carcinoma

NCT07317609 2026-01-05

Endosurgery-02

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT06722183 2025-12-24

FUTURE

33 enrolled

Colorectal Neoplasms

NCT07059299 2025-12-19

NeoTISLEGA

18 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07243691 2025-11-24

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma

Phase NA Recruiting

33 enrolled

Carcinoma, Hepatocellular

NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Phase 1/2 Recruiting

66 enrolled

Disease, Colorectal Neoplasms

NCT05768932 2025-10-15

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

BreastGastrointestinalOther hematologic neoplasm

260 enrolled

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT06529523 2025-10-07

Tislelizumab in People With Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT06893380 2025-09-15

GENTIS

Recruiting

61 enrolled

Biliary Tract Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

269 enrolled

Stomach Neoplasms

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT06446726 2025-06-06

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

92 enrolled

Stomach Neoplasms

NCT06332274 2025-05-13

UMBRELLA

GastrointestinalSarcomaThoracic

717 enrolled

Colonic Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06848465 2025-05-11

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

9 enrolled

Colorectal Neoplasms

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT05984602 2025-04-15

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

10 enrolled

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06881537 2025-03-18

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

15 enrolled

Locally Recurrent Colorectal Cancer

NCT04954781 2025-02-27

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1/2 Recruiting

51 enrolled

Stomach Neoplasms

NCT05920863 2025-02-11

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

35 enrolled

Carcinoma, Hepatocellular

NCT05532059 2025-02-10

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

100 enrolled

Cholangiocarcinoma

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT04615143 2025-01-09

TALENT

80 enrolled

Carcinoma, Hepatocellular

NCT06760858 2025-01-07

A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer

Recruiting

122 enrolled

Stomach Neoplasms

NCT06430658 2024-12-27

NEXUS-2

90 enrolled

Phase EARLY_PHASE1 Recruiting

Esophageal Neoplasms

NCT06690476 2024-11-15

Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma

74 enrolled

Esophageal Squamous Cell Carcinoma

NCT06520683 2024-11-07

SMALLER

180 enrolled

Colorectal Neoplasms

NCT06646588 2024-10-17

SJZ-RMEEC01

67 enrolled

Esophageal Neoplasms

NCT06354140 2024-07-17

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT06451211 2024-06-11

Neo-ICEBOAT

53 enrolled

Stomach Neoplasms

NCT04799548 2024-05-23

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

71 enrolled

Stomach Neoplasms

NCT05515315 2024-02-07

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

93 enrolled

Immunotherapy Esophagus Cancer

NCT06061146 2023-12-26

TCRTOE

136 enrolled

Esophageal Neoplasms

NCT05360277 2023-12-12

CAMCO2

52 enrolled

Metastatic Colorectal Cancer，NED

NCT06056336 2023-09-28

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

73 enrolled

Esophageal Squamous Cell Carcinoma

NCT05984342 2023-08-09

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT05687357 2023-04-19

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

140 enrolled

Stomach Neoplasms

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

40 enrolled

Carcinoma, Hepatocellular

NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

38 enrolled